NDAORALTABLET
Approved
Jun 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
5/8 — Partial
BENICAR HCT (olmesartan medoxomil-hydrochlorothiazide) by Cosette is (ace, kininase ii). First approved in 2003.
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BENICAR HCT is a fixed-dose combination of olmesartan medoxomil (an angiotensin II receptor blocker) and hydrochlorothiazide (a thiazide diuretic) for oral treatment of hypertension. Olmesartan selectively blocks AT1 angiotensin II receptors to reduce vasoconstriction, while HCTZ acts as a diuretic to reduce plasma volume; together they provide complementary antihypertensive effects. The product is indicated for patients requiring dual-agent blood pressure control.
$7MPart D
LOE ApproachingDeclining
This product is in a mature/approaching loss-of-exclusivity phase with modest spending and minimal Part D volume, signaling a contracting field team and shifting focus to post-LOE generic management.
Mechanism of Action
(ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation and renal reabsorption of sodium. Olmesartan blocks the vasoconstrictor effects of…
Pharmacologic Class:
Thiazide Diuretic
Indications
Worked on BENICAR HCT at Cosette? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.